Antimicrobial composition for use in otorhinolaryngology

FIELD: pharmacology.

SUBSTANCE: antimicrobial composition for use in otorhinolaryngology containing hydroxymethylquinoxaline dioxide, polyvinylpyrrolidone and dexamethasone is described, with the following component ratio, wt %: polyvinylpyrrolidone 45.0-55.0, hydroxymethylquinoxaline dioxide solution 10 mg/ml 30.0-33.0, dexamethasone solution 4 mg/ml 12.0-25.0.

EFFECT: antimicrobial composition has a prolonged action due to its high viscosity and adsorption capacity, providing long-term exposure to active substances and reducing the incidence of invasive procedures in otorhinolaryngology.

2 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention deals with application of composition, which includes hydrolysate of pea protein and/or peptide for obtaining composition for treatment and/or prevention of infection Helicobacter pylori (versions), as well as such compositions (versions). Characterised compositions include lipid, protein and carbohydrate component, in which protein component includes protein source, which consists of pea protein hydrolysate, obtained by hydrolysis with protease, different from chymotrypsin, or from peptides, selected from group, which consists of Xaan-Asp-Phe-Leu-Glu-Asp-Ala-Phe-Asn-Val-Asn-Arg-Xaam and Xaan-Glu-Leu-Ala-Phe-Pro-Gly-Ser-Ala-Gln-Glu-Val-Asp-Arg-Xaam, where each Xaa independently can be any amino acid, and n and m are integer numbers, independently varying from 0-10, where peptide is contained in pea protein hydrolysate, or from both.

EFFECT: claimed inventions make it possible to treat or prevent diseases, caused by Helicobacter pylori infection, and/or diseases, associated with infection Helicobacter pylori in mammals.

17 cl, 2 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.

EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and describes pharmaceutical composition, including therapeutically effective quantity of compound, which has the following structure: , where compound in pharmaceutical composition is present in quantity, efficient for treatment or prevention of antibacterial infection in mammalian subject. Methods of obtaining and application of said dosed forms or pharmaceutical compositions are also claimed.

EFFECT: obtaining composition for treatment or prevention of antibacterial infection in mammalian subject.

15 cl, 8 tbl, 5 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.

EFFECT: declared group of inventions is highly effective in treating bovine mastitis.

3 cl, 5 tbl, 1 ex

Antimicrobial agent // 2556509

FIELD: medicine.

SUBSTANCE: compound 2-(1'-hydroxy-4'-isopropenyl-1'-methylcyclohexyl-2'-thio)-methylethanoate having structural formula I: is applicable as an antimicrobial agent.

EFFECT: using the compound of formula I possessing antimicrobial activity provides treating infectious processes caused by susceptible organisms.

5 tbl

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to field of veterinary. Claimed are: vaccine, aimed against actinobacillous pleuropneumonia, including lipopolysaccharide in complex with one or more repeats of ApxI, ApxII and ApxIII toxins, separated from bacterial culture and polymyxin to reduce symptoms of endotoxic shock, caused by lipopolysaccharide, method of obtaining such vaccine, application of polymyxin to reduce endotoxic shock symptoms when vaccine is introduced, in which polymixyn is added into vaccine in dose from 2.6 to 60 mcg/ml.

EFFECT: claimed group of inventions provides effective means and methods to reduce endotoxic shock symptoms, caused by lipopolysaccharide, when vaccine against actinobacillous pleuropneumonia is introduced to animal.

14 cl, 4 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: complex antibacterial agent for animals, containing a compound from the group of fluoroquinolones and auxiliary substances, characterised in that it additionally comprises a compound from the group of pleuromutilins in an effective amount.

EFFECT: invention is effective against vegetative and spore forms of bacteria, it is harmless, has no allergenic properties, has a stimulating effect on the indices of humoral immune response, and is stable during storage.

6 cl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to a strain of the pathogen of pseudomonosis of pigs of the collection of Federal state budgetary institution "VGNKI", deposited under the name "Pseudomonas aeruginosa No.9" and the registration number "No.9-DEP", intended for production of a vaccine against pseudomonosis of pigs.

EFFECT: invention provides high immunogenic activity and the ability of production of the vaccine against pseudomonosis of pigs.

4 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a microbiologically stable pharmaceutical composition containing an active agent specified in prostaglandins, and a carrier. The carrier contains an aqueous electrochemically activated saline containing 1 to 500 mg/l of free chlorine and having an oxidation-reduction potential from +150 to +1350 mV. The active agent is present in a phase separated from the electrochemically activated saline; the electrochemically activated saline is a hypochlorite solution.

EFFECT: invention refers to using the pharmaceutical composition for treating and/or preventing dry eye syndrome and for cleansing contact lenses.

14 cl, 5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a composition for preventing and treating allergic conjunctivitis and keratoconjunctivitis, containing cromoglicic acid, boric acid and water-soluble polymers specified in a group of: carbomer, hypromellose, macrogol and polyvinylpyrrolidone with the components of the composition taken in specific relations, g in 1 ml of the mixture.

EFFECT: invention provides the better reduction of the inflammatory process and symptoms of the disease; there are also ensured ease of use with a smaller frequency of administration, prolonged action and no side effects.

5 ex

FIELD: medicine.

SUBSTANCE: invention refers to a moulded sorbent with the antibacterial properties for treating endometritis, representing nanodispersed mesoporous carbon having a specific adsorption surface of no more than 50 m2/g and a crushing strength of not less than 20 kg/cm2, containing polyvinylpyrrolidone in an amount of not less than 5.0%, characterised by the fact that it is presented in the form of cylinders 2-4mm in diameter, 15-25mm long with one inner circular passage, to a method of treating it, as well as to a method of treating endometritis.

EFFECT: higher clinical effectiveness.

3 cl, 10 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention represents an antimicrobial agent for preventing an implant-associated infection containing gentamicin sulphate 0.96 g, dioxidine 1.0 g, medium-molecular-weight medical collidone (molecular weight 30000D) 10.0 g, distilled water up to 100.0 ml.

EFFECT: extending the range of products preventing the developing implant-associated infection and prevents preserving the antimicrobial activity of the tissues surrounding the implantation area.

2 cl, 1 ex, 3 tbl

FIELD: veterinary medicine.

SUBSTANCE: agent for treatment of inflammation of udder of cows comprises 10-12 g of crystalline iodine, 100-102 g of polyvinylpyrrolidone and additionally in 1000 g/ml: emulsion wax 10-12; glycerol monostearate 50-52; beewax 10-12; refined sunflower oil 77-78; medical vaseline oil 28-29; glycerol 35-37; purified water - the rest to 1000 ml.

EFFECT: agent enables to carry out for short term the effective treatment of fibrinous, serous and suppurative mastitis and avoid the use of antibiotics and their derivatives, sulphanilamides and nitrofurans and thus to eliminate the negative side effect of the agent on animal body, as well as to reduce the economic cost more than 3 times.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery. A polyethylene tube is inserted into a mesentery. A solution containing proserine in a dose of up to 50 mg is introduced through the inserted tube. A synovial fluid 2 ml dissolved in normal saline 10 ml is additionally administered along the enteroenteroanastomosis.

EFFECT: method provides preventing peritoneal adhesions following the abdominal surgical operation by administering the preparations promoting better peristalsis and slide of the intestinal loop in the abdominal cavity.

1 tbl

FIELD: chemistry.

SUBSTANCE: N-vinylpyrrolidone-based copolymer in form of pharmaceutically acceptable additive salts of acids is represented by general formula (I), where R stands for hydrogen or methyl; content of monomer units n constitutes 25-90 mol.%; X stands for anion of pharmaceutically acceptable inorganic or organic acid; k equals 1 or 2; m takes values from 0.1 to 1.0; and average-viscosity molecular weight of copolymer Mµ equals 15-150 kDa.

EFFECT: invention makes it possible to extend arsenal of biologically active copolymers, which have improved characteristics of solubility, and which demonstrate larger activity as immunostimulant, prolonger of antibiotics action, activator of IL-1 production and phagocytosis than known analogous compounds.

6 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: viscoelastic solution for the posterior hyaloid contrast enhancement contains a colouring agent, methyl cellulose, hyaluronic acid, low polyvinyl pyrrolidone and injectable water. The colouring agent is presented by trypan blue and/or brilliant blue. The ingredients are used in the declared ratio.

EFFECT: lower toxic effect of the retina, improved intraoperative visualisation of cortical layers of the vitreous body.

3 ex

FIELD: veterinary medicine.

SUBSTANCE: agent for prevention of mastitis in dairy cows in the dry period, characterised in that it contains as ingredients the polymer PVP/VA, silicone, polyhexamethylene biguanide, ethyl alcohol, glycerol - as emollient component, gelation agents - triethanolamine and carbopol and purified water in the following ratio of ingredients, %: polymer PVP/VA 9-10; silicone 5-6; ethyl alcohol 35-40; polyhexamethylene biguanide 0.008-0.01; glycerol 5; gelation agents - triethanolamine and carbopol 0.1; purified water - the rest.

EFFECT: method enables to minimise or eliminate the use of chemotherapeutic agents, antibiotics and their derivatives, sulphonamides, nitrofurans and eliminate the side effect of the agent on animal body, as well as to reduce the number of visits of the veterinarian during the dry period of cows, to improve the preventive efficacy.

1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.

EFFECT: providing a composition which stimulates a reparative process in external protective tissue, having anti-inflammatory and radioprotective action.

1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutical compositions for the combined therapy of arthropathies, except for rheumatoid arthritis, degenerative disk diseases, joint pains and/or autoimmune disease (particularly alopecia, neurodermitis). There are presented: a pharmaceutical composition for the above application containing a glucocorticoid, exosomes prepared of autologous blood and a cytokine antagonist ortokin or anakinra; a method for producing it involving the pharmaceutical composition containing the exosomes prepared of autologous blood and the cytokine antagonist ortokin or anakinra, and the pharmaceutical composition containing the glucocorticoid and the cytokine antagonist ortokin or anakinra, and versions of using the above substances for producing the pharmaceutical composition for the combined therapy.

EFFECT: technical effect consists in achieving the synergetic effect both on the exposure rate and remote outcomes of the specified diseases with reducing side effects of the glucocorticoid (cortisone).

33 cl, 1 dwg

Up!